People · Operator
Named in public records as an officer, director or promoter · active 2019–2025 · Other, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Oncorus, Inc. | — | Other | Series C | $115.1M | $921.8M | 2019 |
| Newleos Therapeutics, Inc. | — | Biotechnology | Series C | $93.4M | $659.9M | 2025 |
John McCabe at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John McCabe on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Luke Evnin | 1 | 12 |
| Cameron Wheeler | 1 | 9 |
| Briggs Morrison | 1 | 8 |
| Christoph Westphal | 1 | 8 |
| Alon Lazarus | 1 | 7 |
| David Donabedian | 1 | 4 |
| Raymond Camahort | 1 | 4 |
| Robert Kirkman | 1 | 3 |
| Mitchell Finer | 1 | 3 |
| Robert Hadfield | 1 | 2 |
| Thomas Chalberg | 1 | 2 |
| Ming Cheah | 1 | 1 |
| Marc Recht | 1 | 1 |
| Theodore Ashburn | 1 | 1 |
| Mary Kay Fenton | 1 | 1 |
| Spencer Nam | 1 | 1 |
| Christophe Queva | 1 | 1 |
| Cyrus Mozayeni | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.